Indian biopharmaceutical company Biocon Limited (NSE:BIOCON) is seeking a partner to test generic versions of Novo Nordisk's (CPH:NOVO-B) diabetes drug Ozempic and weight loss treatment Wegovy in China, Reuters reported on Thursday.
An unnamed senior executive told the news agency that Biocon is looking for a Chinese partner for clinical trials on patients in order to sell the drug in China.
Biocon is aiming to launch generic versions of the drugs globally.
Patent protection on semaglutide, a key ingredient in both Ozempic and Wegovy, is due to expire in China in early 2026.
Bionpharma and STEERLife's Etravirine tablets approved by US FDA
ScinoPharm Taiwan secures first US FDA approval for complex multiple sclerosis generic
ScinoPharm Taiwan's Glatiramer Acetate Injection approved by US FDA
Accord Healthcare launches Clomiphene tablets in US market
Zentiva receives ESG Transparency Award 2025
Galmed Pharmaceuticals reports topline results for combination of Aramchol, Stivarga and metformin
Ingenus Pharmaceuticals' generic equivalent to Premarin receives US FDA approval
EirGenix signs second global exclusive licensing deal with Sandoz